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Chondrosarcoma Models: Understanding Chemoresistance Mechanisms  
for Use in Targeted Treatment
1.  Activity of anti-apoptotic Bcl-2 family members plays a role in the chemoresistance of 
chondrosarcoma. This thesis
2.  Heterogeneous tyrosine kinase signaling in chondrosarcoma poses a challenge for 
finding a uniform target and necessitates the development of personalized therapy. This 
thesis
3.  Combination strategies of conventional chemotherapy with new targeted therapeutics 
are key to overcoming chemoresistance in chondrosarcoma. This thesis
4.  Completion of the bench to bedside pipeline is a crucial step towards developing new 
treatment strategies for chondrosarcoma. This thesis
5.  From a clinical perspective, pretreatment with novel, potent Bcl-2 inhibitors, either 
alone or in combination with conventional chemotherapeutic agents,  hold significant 
promise for providing beneficial clinical outcomes. Thomas, Expert Opin Ther 
Targets, 2013: 17(1):61-75
6.  Over the past 15 years, protein kinases have become the most important drug targets in 
the field of anti-tumor drugs. Cohen, ACS Chem Biol, 2013: 18(1):96-104
7.  Every step of the journey of a protein biomarker from the bench to the clinic needs to 
be meticulously planned and executed in order to succeed (Pavlou, Clin Chem, 2013: 
59(1):147-157) and the development of new drugs relies heavily on animal studies to 
provide a framework for human clinical trials. Zhou, AAPS J, 2011: 13(1):111-20
8. Phase I trials show well tolerability of dual inhibition using PI3K and MEK inhibitors 
which may be needed to treat cancers with driver mutations that cannot be directly 
targeted, such as mutational activation of RAS. Britten, Cancer Chemother Pharmacol 
2013: 71:1359-1409
9.  There are things known and there are things unknown, and in between there are the 
doors of perception. Aldous Huxley
10.  You build on failure, you use it as a stepping stone. Johnny Cash
11.  An Fortschritt glauben heißt nicht glauben daß ein Fortschritt schon geschehen ist. (To 
believe in progress does not mean progress has been made) Kafka, Aphormismen II, 4
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